Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Michael Crowley sold 700 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total transaction of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Bio-Rad Laboratories, Inc. (BIO) traded up 0.41% during trading on Friday, reaching $215.89. 232,899 shares of the company traded hands. The stock has a market capitalization of $6.40 billion, a PE ratio of 426.66 and a beta of 0.91. The firm has a 50 day moving average of $229.16 and a 200 day moving average of $212.40. Bio-Rad Laboratories, Inc. has a 52 week low of $147.68 and a 52 week high of $242.79.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/11/bio-rad-laboratories-inc-nysebio-evp-michael-crowley-sells-700-shares.html.

A number of institutional investors have recently modified their holdings of the company. Great West Life Assurance Co. Can increased its position in shares of Bio-Rad Laboratories by 3.9% in the first quarter. Great West Life Assurance Co. Can now owns 12,380 shares of the medical research company’s stock worth $2,467,000 after buying an additional 469 shares during the period. Advisory Services Network LLC purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $115,000. Oregon Public Employees Retirement Fund increased its position in shares of Bio-Rad Laboratories by 1.4% in the first quarter. Oregon Public Employees Retirement Fund now owns 7,225 shares of the medical research company’s stock worth $1,440,000 after buying an additional 100 shares during the period. Dowling & Yahnke LLC purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $201,000. Finally, Old Mutual Global Investors UK Ltd. purchased a new position in shares of Bio-Rad Laboratories during the first quarter worth approximately $318,000. 63.73% of the stock is currently owned by institutional investors.

BIO has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price target on the stock in a report on Monday, May 1st. Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price target for the company from $220.00 to $195.00 in a report on Wednesday, June 28th. BidaskClub upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $250.00 price target on shares of Bio-Rad Laboratories in a report on Thursday, April 27th. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Bio-Rad Laboratories currently has a consensus rating of “Buy” and an average target price of $228.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.